Clinical Trials Sponsored by Ortho Biotech Products, L.P.

Total 52 results

Ortho Biotech Products, L.P.

Completed

Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia (DOSE)

Cancer | Anemia
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy

Leukemia | Anemia | Hodgkin Disease | Lymphoma, Non-hodgkin
Ortho Biotech Products, L.P.

Terminated

A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Neoplasms | Anemia
Ortho Biotech Products, L.P.

Withdrawn

Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis

Rheumatoid Arthritis | Anemia
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

Anemia | Hepatitis C
Ortho Biotech Products, L.P.

Completed

NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection

Anemia | Hepatitis C | HIV
Ortho Biotech Products, L.P.

Completed

An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)

HIV Infections | Anemia
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)

Anemia | Chronic Renal Insufficiency
Ortho Biotech Products, L.P.

Terminated

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Quality of Life | Breast Neoplasms | Anemia | Hemoglobins | Chemotherapy, Adjuvant
Ortho Biotech Products, L.P.

Completed

Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia

Anemia | Chemotherapy
Ortho Biotech Products, L.P.

Terminated

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Cancer | Anemia | Chemotherapy
Ortho Biotech Products, L.P.

Terminated

A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.

Anemia | Chronic Renal Insufficiency
Ortho Biotech Products, L.P.

Terminated

A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)

Kidney Diseases | Anemia
Aptium Oncology Research Network
Ortho Biotech Products, L.P.

Unknown

Phase II Study in Patients With Operable Breast Cancer

Breast Cancer

United States
Brigham and Women's Hospital
Ortho Biotech Products, L.P.

Terminated

Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial (ERIN)

Contrast Induced Nephropathy

United States
Morton Plant Mease Health Care
Ortho Biotech Products, L.P.

Terminated

Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer

Prostate Cancer

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Cancer | Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Cancer | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

Rheumatoid Arthritis | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Anemia | Aged | Hemoglobins
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Kidney Diseases | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Cancer | Anemia | Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

Anemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

Cancer | Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients

Anemia | HIV
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Stomach Neoplasms | Rectal Neoplasms
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Anemia | Aged | Hemoglobins
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

PROCRIT and Short-Term Outcomes in Orthopedic Surgery

Anemia | Surgery, Arthroscopy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Critical Illness | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Treatment of Anemia in Diabetic Subjects With CKD

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

The Duration Study

Anemia
The Alvin and Lois Lapidus Cancer Institute
Ortho Biotech Products, L.P.

Unknown

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

United States
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

HIV

United States
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

HIV | Infectious

United States, Canada, Puerto Rico
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients (INROADS)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers

HIV
Indiana University
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study

HIV Infections | Inflammation | Insulin Resistance | Endothelial Function | Lipids

United States
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

HIV

United States
University of Southern California
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

HIV

United States
University of Colorado, Denver
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

HIV Infections | Hyperlipidemia

United States
University of Southern California
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Carcinoma | Cancer

United States
Ruth M. Rothstein CORE Center
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects (DRIVESHAFT)

HIV

United States
Johnson & Johnson Pharmaceutical Research & Development...
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Myeloma | M-Protein | Myeloma Proteins
Johnson & Johnson Pharmaceutical Research & Development...
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Johnson & Johnson Pharmaceutical Research & Development...
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Terminated

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Metastatic Breast Cancer

United States

3

Subscribe